This product is a selective anticholinergic drug with high affinity for muscarinic receptors of gastric parietal cells, but low affinity for muscarinic receptors of smooth muscle, myocardium and salivary glands. When using general therapeutic doses, it can only inhibit gastric acid secretion, and rarely has side effects on pupils, gastrointestinal smooth muscle, heart, salivary glands and bladder muscles like other anticholinergic drugs. Increasing the dose can inhibit saliva secretion, and only large doses can inhibit gastrointestinal smooth muscle and cause tachycardia. This product cannot pass through the blood-brain barrier, so it does not affect the central nervous system. After oral, intramuscular or intravenous administration of this product, both basal gastric acid secretion and gastric acid secretion caused by exogenous pentagastrin and insulin are inhibited. This product has little effect on the pH of gastric juice, mainly reducing the secretion of gastric juice (including pepsinogen and pepsin), thereby reducing the maximum gastric acid secretion and the highest acid secretion.

It has a strong antitussive effect, and has antihistamine, smooth muscle spasm relief, anti-inflammatory and local anesthetic effects. The antitussive effect appears 30 to 60 minutes after taking the medicine and lasts for 4 to 6 hours or longer.

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most beta-lactamases and have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, and Clostridium.

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most β-lactamases and have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, and Clostridium.